S1331 Colonic Bioactivation and Potent TNFa Inhibition of PALI-2108 in Human ex-vivo Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis

Joie Bernard,Florian Rieder,Christophe Mellon,Mitchell Jones
DOI: https://doi.org/10.14309/01.ajg.0001034692.85987.c1
2024-10-26
The American Journal of Gastroenterology
Abstract:PDE4 is a key enzyme in cAMP hydrolysis. Inhibition elevates cAMP, downregulates inflammatory cytokines, and prevents local infiltration of inflammatory cells. Approved PDE4 inhibitors include roflumilast for chronic obstructive pulmonary disease and apremilast for psoriasis. Despite the development of subtype specific PDE4 inhibitors, oral administration and systemic distribution has resulted in central nervous system (CNS) toxicity (headaches, nausea or vomiting) leading to discontinuation of therapy and limiting potential efficacy. Targeted and better-tolerated oral PDE4 inhibitors remain an unmet need in inflammatory bowel disease (IBD).
gastroenterology & hepatology
What problem does this paper attempt to address?